• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Medtronic plc.

    11/19/25 11:05:48 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001533098
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Medtronic plc
    SEC File Number
    001-36820
    Address of Issuer
    BUILDING TWO PARKMORE BUSINESS PARK WEST
    GALWAY
    IRELAND
    H91 4K49
    Phone
    01135314381700
    Name of Person for Whose Account the Securities are To Be Sold
    Smith Gregory L
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    300003058452.26128268588211/19/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/30/2022ESPP PurchaseIssuerCheckbox not checked9106/30/2022Cash
    Common09/30/2022ESPP PurchaseIssuerCheckbox not checked12309/30/2022Cash
    Common03/31/2023ESPP PurchaseIssuerCheckbox not checked10303/31/2023Cash
    Common04/05/2023Restricted Stock VestingIssuerCheckbox not checked1062004/05/2023Compensation
    Common04/14/2023Restricted Stock VestingIssuerCheckbox not checked8804/14/2023Compensation
    Common06/30/2023ESPP PurchaseIssuerCheckbox not checked8006/30/2023Cash
    Common09/29/2023ESPP PurchaseIssuerCheckbox not checked10609/29/2023Cash
    Common12/29/2023ESPP PurchaseIssuerCheckbox not checked1612/29/2023Cash
    Common03/28/2024ESPP PurchaseIssuerCheckbox not checked9503/28/2024Cash
    Common06/28/2024ESPP PurchaseIssuerCheckbox not checked9006/28/2024Cash
    Common07/31/2024Restricted Stock VestingIssuerCheckbox not checked301807/31/2024Compensation
    Common08/02/2024Restricted Stock VestingIssuerCheckbox not checked444608/02/2024Compensation
    Common09/30/2024ESPP PurchaseIssuerCheckbox not checked10709/30/2024Cash
    Common07/31/2025Restricted Stock VestingIssuerCheckbox not checked294207/31/2025Compensation
    Common08/01/2025Restricted Stock VestingIssuerCheckbox not checked807508/01/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Gregory L. Smith.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    11/19/2025$111.00Sell → Neutral
    Goldman
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    More analyst ratings

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President Cardiovascular Kiil Harry Skip sold $788,048 worth of Ordinary Shares (8,605 units at $91.58), decreasing direct ownership by 19% to 35,615 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    9/5/25 4:18:13 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,052 units of Ordinary Shares, decreasing direct ownership by 2% to 51,939 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/21/25 4:22:11 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medtronic upgraded by Goldman with a new price target

    Goldman upgraded Medtronic from Sell to Neutral and set a new price target of $111.00

    11/19/25 8:47:22 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Wolfe Research

    Wolfe Research upgraded Medtronic from Underperform to Peer Perform

    6/30/25 7:56:30 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Leerink Partners initiated coverage on Medtronic with a new price target

    Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

    6/16/25 7:51:25 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    SEC Filings

    View All

    SEC Form 144 filed by Medtronic plc.

    144 - Medtronic plc (0001613103) (Subject)

    11/19/25 11:05:48 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    11/18/25 6:47:14 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Leadership Update

    8-K - Medtronic plc (0001613103) (Filer)

    11/3/25 5:21:46 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum

    Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpointGAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidanceRaising FY26 guidance: 5.5% organic revenue growth, $5.62-$5.66 adjusted

    11/18/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

    NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: 2025 Jefferies London Healthcare Conference – November 17-20, 2025 (London, UK) Management will host one-on-one meetings with investors on Tuesday, November 18. Piper 37th Annual Healthcare Conference – December 2-4, 2025 (New York, NY) M

    11/11/25 9:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

    Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon ("Virtue SAB") trial versus commercially available paclitaxel-coated balloon Demonstrated partnership-driven business model execution with expanded strategic collaboration with Medtronic and new right of first refusal agreement with Terumo NEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO,

    11/10/25 4:10:38 PM ET
    $LGND
    $MDT
    $OBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medicinal Chemicals and Botanical Products

    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum

    Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpointGAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidanceRaising FY26 guidance: 5.5% organic revenue growth, $5.62-$5.66 adjusted

    11/18/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed to Host Business Update Call on November 12, 2025

    NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing developments, including the Company's additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agr

    11/3/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Medtronic reports first quarter fiscal 2026 financial results

    11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl

    8/19/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/15/23 3:34:14 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care